Inosine reduces inflammation and improves survival in a murine model of colitis

American Journal of Physiology - Gastrointestinal and Liver Physiology

Volumn 284, Issue 1 47-1, 2003, Pages

  Mabley, J G ^a   Pacher, P ^a   Liaudet, L ^b   Soriano, F G ^b   Hasko, G ^a   Marton, A ^a   Szabo, C ^a,b   Salzman, A L ^a  

^a INOTEK CORPORATION   (United States)

^b RUTGERS NEW JERSEY MEDICAL SCHOOL   (United States)

Author keywords

Colon; Cytokines; Dextran sodium sulfate; Purine

Indexed keywords

ADENOSINE; CHEMOKINE; CYTOKINE; DEXTRAN SULFATE; INOSINE; MALONALDEHYDE; MYELOPEROXIDASE; PURINE DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CELL INFILTRATION; COLITIS; COLON INJURY; CONTROLLED STUDY; DOSE RESPONSE; INFLAMMATION; INFLAMMATORY CELL; LIPID PEROXIDATION; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; RECTUM HEMORRHAGE; SURVIVAL;

EID: 0037230080     PISSN: 01931857     EISSN: None     Source Type: Journal    
DOI: 10.1152/ajpgi.00060.2002     Document Type: Article

References (44)

1. Ames BN, Cathcart R, Schwiers E, and Hochstein P. Uric acid provides an antioxidant defense in humans against oxidant- and radical-caused aging and cancer: A hypothesis. Proc Natl Acad Sci USA 78: 6858-6862, 1981.
2. Apasov S, Koshiba M, Redegeld F, and Sitkovsky MV. Role of extracellular ATP and P1 and P2 classes of purinergic receptors in T-cell development and cytotoxic T lymphocyte effector functions. Immunol Rev 146: 5-19, 1995.
3. Barankiewicz J and Cohen A. Purine nucleotide metabolism in resident and activated rat macrophages in vitro. Eur J Immunol 15: 627-631, 1985.
4. Becker BF, Reinholz N, Ozcelik T, Leipert B, and Gerlach E. Uric acid as radical scavenger and antioxidant in the heart. Pflügers Arch 415: 127-135, 1989.
5. Bennett CF, Kornbrust D, Henry S, Stecker K, Howard R, Cooper S, Dutson S, Hall W, and Jacoby HI. An ICAM-1 antisense oligonucleotide prevents and reverses dextran sulfate sodium-induced colitis in mice. J Pharmacol Exp Ther 280: 988-1000, 1997.
6. Cole AW and Palmer TN. Action of purine nucleosides on the release of intracellular enzymes from rat lymphocytes. Clin Chim Acta 92: 93-100, 1979.
7. Cooper HS, Murthy SN, Shah RS, and Sedergran DJ. Clinicopathologic study of dextran sulfate sodium experimental murine colitis. Lab Invest 69: 238-249, 1993.
8. Cronstein BN. Adenosine, an endogenous anti-inflammatory agent. J Appl Physiol 76: 5-13, 1994.
9. De Rougemont D, Brunner FP, Torhorst J, Wunderlich PF, and Thiel G. Superficial nephron obstruction and medullary congestion after ischemic injury: Effect of protective treatments. Nephron 31: 310-320, 1982.
10. Dieleman LA, Palmen MJ, Akol H, Bloemena E, Pena AS, Meuwissen SG, and Van Rees EP. Chronic experimental colitis induced by dextran sulphate sodium (DSS) is characterized by Th1 and Th2 cytokines. Clin Exp Immunol 114:385-391, 1998.
11. Egger B, Bajaj-Elliott M, MacDonald TT, Inglin R, Eysselein VE, and Buchler MW. Characterisation of acute murine dextran sodium sulphate colitis: Cytokine profile and dose dependency. Digestion 62: 240-248, 2000.
12. Elson CO, Sartor RB, Tennyson GS, and Riddell RH. Experimental models of inflammatory bowel disease. Gastroenterology 109: 1344-1367, 1995.
13. Fuss IJ, Marth T, Neurath MF, Pearlstein GR, Jain A, and Strober W. Anti-interleukin 12 treatment regulates apoptosis of Th1 T cells in experimental colitis in mice. Gastroenterology 117: 1078-1088, 1999.
14. Garcia Soriano F, Liaudet L, Marton A, Hasko G, Batista Lorigados C, Deitch EA, and Szabo C. Inosine improves gut permeability and vascular reactivity in endotoxic shock. Crit Care Med 29: 703-708, 2001.
15. Hans W, Scholmerich J, Gross V, and Falk W. Interleukin-12 induced interferon-gamma increases inflammation in acute dextran sulfate sodium induced colitis in mice. Eur Cytokine Netw 11: 67-74, 2000.
16. 2a. receptor-dependent and independent mechanisms. FASEB J 14: 2065-2074, 2000.
17. Hasko G, Kuhel DG, Nemeth ZH, Mabley JG, Stachlewitz RF, Virag L, Lohinai Z, Southan GJ, Salzman AL, and Szabo C. Inosine inhibits inflammatory cytokine production by a posttranscriptional mechanism and protects against endotoxin-induced shock. J Immunol 164: 1013-1019, 2000.
18. Hasko G, Nemeth ZH, Vizi ES, Salzman AL, and Szabo C. An agonist of adenosine A3 receptors decreases interleukin-12 and interferon-gamma production and prevents lethality in endotoxemic mice. Eur J Pharmacol 358: 261-268, 1998.
19. Hasko G and Szabo C. Regulation of cytokine and chemokine production by transmitters and co-transmitters of the autonomic nervous system. Biochem Pharmacol 56: 1079-1087, 1998.
20. Hooper DC, Bagasra O, Marini JC, Zborek A, Ohnishi ST, Kean R, Champion JM, Sarker AB, Bobroski L, Farber JL, Akaike T, Maeda H, and Koprowski H. Prevention of experimental allergic encephalomyelitis by targeting nitric oxide and peroxynitrite: Implications for the treatment of multiple sclerosis. Proc Natl Acad Sci USA 94: 2528-2533, 1997.
21. Jurkowitz MS, Litsky ML, Browning MJ, and Hohl CM. Adenosine, inosine, and guanosine protect glial cells during glucose deprivation and mitochondrial inhibition: Correlation between protection and ATP preservation. J Neurochem 71: 535-548, 1998.
22. Kojouharoff G, Hans W, Obermeier F, Mannel DN, Andus T, Scholmerich J, Gross V, and Falk W. Neutralization of tumour necrosis factor (TNF) but not of IL-1 reduces inflammation in chronic dextran sulphate sodium-induced colitis in mice. Clin Exp Immunol 107: 353-358, 1997.
23. Liaudet L, Mabley JG, Pacher P, Szabo C, and Salzman AL. The novel and potent peroxynitrite scavenger, FP 15, protects against development of colitis in mice (Abstract). FASEB J 16: A599, 2002.
24. Liaudet L, Mabley JG, Pacher P, Virag L, Soriano FG, Marton A, Hasko G, Deitch EA, and Szabo C. Inosine exerts a broad range of anti-inflammatory effects in a murine model of acute lung injury. Ann Surg 235: 568-578, 2002.
25. Liaudet L, Mabley JG, Soriano FG, Pacher P, Marton A, Hasko G, and Szabo C. Inosine reduces systemic inflammation and improves survival in septic shock induced by cecal ligation and puncture. Am J Respir Crit Care Med 164: 1213-1220, 2001.
26. Mabley JG, Suarez-Pinzon WL, Pacher P, Hasko G, Rabinovitch A, and Szabo C. Inosine protects against both the primary disease and rejection of syngeneic islet grafts in NOD mice (Abstract). FASEB J 16: A985, 2002.
27. Marak GE Jr, de Kozak Y, Faure JP, Rao NA, Romero JL, Ward PA, and Till GO. Pharmacologic modulation of acute ocular inflammation. I. Adenosine. Ophthalmic Res 20: 220-226, 1988.
28. Marton A, Pacher P, Murthy KG, Nemeth ZH, Hasko G, and Szabo C. Anti-inflammatory effects of inosine in human monocytes, neutrophils and epithelial cells in vitro. Int J Mol Med 8: 617-621, 2001.
29. Mazzon E, Dugo L, Li JH, Di Paola R, Genovese T, Caputi AP, Zhang J, and Cuzzoerea S. GPI 6150, a PARP inhibitor, reduces the colon injury caused by dinitrobenzene sulfonic acid in the rat. Biochem Pharmacol 64: 327-337, 2002.
30. McWhinney CD, Dudley MW, Bowlin TL, Peet NP, Schook L, Bradshaw M, De M, Borcherding DR, and Edwards CK, 3rd. Activation of adenosine A3 receptors on macrophages inhibits tumor necrosis factor-a. Eur J Pharmacol 310: 209-216, 1996.
31. + exchanger blockade inhibits enterocyte inflammatory response and protects against colitis. Am J Physiol Gastrointest Liver Physiol 283: G122-G132, 2002.
32. Okayasu I, Hatakeyama S, Yamada M, Ohkusa T, Inagaki Y, and Nakaya R. A novel method in the induction of reliable experimental acute and chronic ulcerative colitis in mice. Gastroenterology 98: 694-702, 1990.
33. Olson AD, DelBuono EA, Bitar KN, and Remick DG. Antiserum to tumor necrosis factor and failure to prevent murine colitis. J Pediatr Gastroenterol Nutr 21: 410-418, 1995.
34. 3 adenosine receptors. J Immunol 156: 3435-3442, 1996.
35. Schrier DJ, Lesch ME, Wright CD, and Gilbertsen RB. The antiinflammatory effects of adenosine receptor agonists on the carrageenan-induced pleural inflammatory response in rats. J Immunol 145: 1874-1879, 1990.
36. Singer II, Kawka DW, Scott S, Weidner JR, Mumford RA, Riehl TE, and Stenson WF. Expression of inducible nitric oxide synthase and nitrotyrosine in colonic epithelium in inflammatory bowel disease. Gastroenterology 111: 871-885, 1996.
37. Szabo C and Dawson VL. Role of poly(ADP-ribose) synthetase in inflammation and ischaemia-reperfusion. Trends Pharmacol Sci 19: 287-298, 1998.
38. Szabo C, Scott GS, Virag L, Egnaczyk G, Salzman AL, Shanley TP, and Hasko G. Suppression of macrophage inflammatory protein (MIP)-la production and collagen-induced arthritis by adenosine receptor agonists. Br J Pharmacol 125: 379-387, 1998.
39. Szabo C, Zingarelli B, and Salzman AL. Role of poly-ADP ribosyltransferase activation in the vascular contractile and energetic failure elicited by exogenous and endogenous nitric oxide and peroxynitrite. Circ Res 78: 1051-1063, 1996.
40. Veerabagu MP, Meguid MM, Oler A, and Levine RA. Intravenous nucleosides and a nucleotide promote healing of small bowel ulcers in experimental enterocolitis. Dig Dis Sci 41: 1452-1457, 1996.
41. Virag L and Szabo C. Purines inhibit poly(ADP-ribose) polymerase activation and modulate oxidant-induced cell death. FASEB J 15: 99-107, 2001.
42. Ward SG, Bacon K, and Westwick J. Chemokines and T lymphocytes: More than an attraction. Immunity 9: 1-11, 1998.
43. Zingarelli B, Cuzzocrea S, Szabo C, and Salzman AL. Mercaptoethylguanidine, a combined inhibitor of nitric oxide synthase and peroxynitrite scavenger, reduces trinitrobenzene sulfonic acid-induced colonic damage in rats. J Pharmacol Exp Ther 287:1048-1055, 1998.
44. Zingarelli B, Szabo C, and Salzman AL. Blockade of poly(ADP-ribose) synthetase inhibits neutrophil recruitment, oxidant generation, and mucosal injury in murine colitis. Gastroenterology 116: 335-345, 1999.